Anteris Technologies Global (NASDAQ:AVR) Shares Down 4.3% After Earnings Miss

Anteris Technologies Global Corp. (NASDAQ:AVR) shares were down 4.3% during trading on Wednesday following a dissappointing earnings announcement. The stock traded as low as $8.59 and last traded at $8.7750. 108,992 shares were traded during trading, a decline of 91% from the average daily volume of 1,171,928 shares. The stock had previously closed at $9.17.

The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). The firm had revenue of $1.01 million for the quarter, compared to the consensus estimate of $1.50 million. Anteris Technologies Global had a negative net margin of 5,148.78% and a negative return on equity of 124.76%. During the same quarter in the prior year, the firm posted ($0.58) earnings per share.

More Anteris Technologies Global News

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: Anteris secured U.S. Medicare reimbursement eligibility under a Centers for Medicare & Medicaid Services national coverage policy for eligible procedures in its global pivotal PARADIGM Trial. The policy could improve trial participation and reduce reimbursement-related barriers at U.S. sites. Anteris Technologies Announces Results for the Second Quarter of 2026
• Positive Sentiment: Quarterly EPS improved from a loss of $0.58 in the year-ago period to a loss of $0.30, suggesting year-over-year progress despite the company remaining unprofitable.
• Neutral Sentiment: Analysts continue to project a full-year loss of approximately $1.14 per share, underscoring that AVR remains a development-stage medical-device company whose valuation depends heavily on clinical and regulatory execution.
• Negative Sentiment: Second-quarter results missed expectations: the company reported a $0.30 per-share loss versus the consensus loss estimate of $0.21, while revenue of $1.01 million fell short of the $1.50 million estimate. Anteris also reported an extremely negative net margin and return on equity. Anteris Technologies Announces Results for the Second Quarter of 2026
• Negative Sentiment: Major shareholder L1 Capital Pty Ltd sold 375,815 shares for about $3.50 million on August 11 and 251,844 shares for approximately $2.29 million on August 10. These transactions reduced its position by 7.25% and 4.63%, respectively, following additional recent sales. Repeated large-holder selling may weigh on investor sentiment and increase perceived supply overhang. SEC Filing

Analyst Upgrades and Downgrades

AVR has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Friday, May 29th. Wall Street Zen raised Anteris Technologies Global from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Barclays boosted their target price on shares of Anteris Technologies Global from $17.00 to $18.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Insider Activity at Anteris Technologies Global

In other news, major shareholder L1 Capital Pty Ltd sold 375,815 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $9.30, for a total value of $3,495,079.50. Following the completion of the sale, the insider directly owned 4,811,341 shares in the company, valued at approximately $44,745,471.30. This trade represents a 7.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 3,000,659 shares of company stock worth $25,174,702 in the last quarter. 4.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Anteris Technologies Global

Hedge funds have recently added to or reduced their stakes in the stock. L1 Capital Pty Ltd increased its position in Anteris Technologies Global by 143.2% in the 3rd quarter. L1 Capital Pty Ltd now owns 6,838,136 shares of the company’s stock valued at $30,772,000 after acquiring an additional 4,026,136 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Anteris Technologies Global during the second quarter worth approximately $56,846,000. ADAR1 Capital Management LLC lifted its position in shares of Anteris Technologies Global by 205.9% during the first quarter. ADAR1 Capital Management LLC now owns 3,789,132 shares of the company’s stock worth $21,030,000 after purchasing an additional 2,550,355 shares in the last quarter. Perceptive Advisors LLC grew its stake in shares of Anteris Technologies Global by 104.4% during the first quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock valued at $19,011,000 after purchasing an additional 1,750,000 shares during the last quarter. Finally, Nantahala Capital Management LLC grew its stake in shares of Anteris Technologies Global by 31.9% during the fourth quarter. Nantahala Capital Management LLC now owns 2,530,910 shares of the company’s stock valued at $12,629,000 after purchasing an additional 612,244 shares during the last quarter.

Anteris Technologies Global Stock Down 4.4%

The firm has a market cap of $853.09 million, a price-to-earnings ratio of -3.92 and a beta of 1.78. The business’s fifty day moving average is $9.15 and its two-hundred day moving average is $7.33.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.